HAVCR2 and acute myeloid leukemia: Azacitidine is currently being combined with other antibody-based therapeutic approaches in AML including anti-CD47 and anti-TIM-3 antibodies2, which provided further motivation for testing in combination with anti-U5 small nuclear ribonucleoprotein (snRNP) antibodies.